

Pre-Clinical Development of EDN-OL1 for Alzheimers Disease

<https://neurodegenerationresearch.eu/survey/pre-clinical-development-of-edn-ol1-for-alzheimers-disease/>

Principal Investigators

XU, XIN

Institution

National Center for Advancing Translational Sciences

Contact information of lead PI

Country

USA

Title of project or programme

Pre-Clinical Development of EDN-OL1 for Alzheimers Disease

Source of funding information

NIH (NIA)

Total sum awarded (Euro)

102953.211

Start date of award

Total duration of award in years

2

Keywords

Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Brain Disorders... Dementia... Neurodegenerative... Neurosciences... Translational Research

Research Abstract

More than 5 million Americans now have Alzheimers disease (AD), the sixth leading cause of death in the United States, and no disease-modifying drug is available. EDN-OL1, a patented antisense phosphorothioate oligonucleotide, crosses the blood-brain barrier after intravenous dosing and reduces production of amyloid precursor protein (APP) and, consequently, amyloid proteins in the brains of mouse models of AD. The clinical benefit to AD patients may best be anticipated as a decrease in the rate of cognitive decline. Edunn requested program assistance to carry out specific tasks for pre-clinical development of EDN-OL1 to support submission of an

Investigational New Drug (IND) application to enable clinical trials for the Alzheimers indication, ultimately leading to FDA approval for treatment of AD patients. The lab has made progress towards the completion of the following studies: – Synthesis of Good Manufacturing Practice (GMP) and non-GMP material – Formulation development

Further information available at:

Types:

Investments < €500k

Member States:

United States of America

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A